- Home
- IGI vs PROK Comparison
IGI vs PROK Comparison
Compare IGI & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IGI | PROK |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.4M | 417.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IGI | PROK |
|---|---|---|
| Price | $16.35 | $2.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 33.9K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 4.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $744,000.00 |
| Revenue This Year | N/A | $918.66 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.13 | $0.46 |
| 52 Week High | $17.79 | $7.13 |
Technical Indicators
Market Signals| Indicator | IGI | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 38.99 | 41.86 |
| Support Level | $16.36 | $2.06 |
| Resistance Level | $16.46 | $2.29 |
| Average True Range (ATR) | 0.11 | 0.17 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 43.24 | 19.67 |
Price Performance
Historical ComparisonAbout IGI Western Asset Investment Grade Defined Opportunity Trust Inc.
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.